A short hashtag-heavy clip on regaining weight after stopping GLP-1 drugs. Few details beyond the title.
Recap by typeshit. Video by DailySoulNourish on TikTok.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
The once-weekly autoinjector is cleared for type 2 diabetes, overweight and obesity. Lilly never officially sold Mounjaro in Russia, and its rights there ended in November 2024.
In the 308-person REMAIN-1 study, Revita patients held onto about 80% of their lost weight versus 67% with sham. Fractyl plans an FDA filing in late 2026.
Loading…